Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2012

01-03-2012 | Research Articles

Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis

Authors: Amir Sonnenblick, Anat Shriki, Eithan Galun, Jonathan H. Axelrod, Hagit Daum, Yakir Rottenberg, Tamar Hamburger, Bela Mali, Tamar Peretz

Published in: Clinical and Translational Oncology | Issue 3/2012

Login to get access
Metadata
Title
Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis
Authors
Amir Sonnenblick
Anat Shriki
Eithan Galun
Jonathan H. Axelrod
Hagit Daum
Yakir Rottenberg
Tamar Hamburger
Bela Mali
Tamar Peretz
Publication date
01-03-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0789-z

Other articles of this Issue 3/2012

Clinical and Translational Oncology 3/2012 Go to the issue

Editorial

Is there any role for new prognostic markers in breast cancer?

Research Articles

PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation

Special Article

Consensus of the Spanish Society of Radiation Oncology (SEOR) Brachytherapy Group on brachytherapy in Breast Cancer

Research Articles

Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians

Research Articles

Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas

Research Articles

Evaluation of ER-α, ER-β1 and ER-β2 expression and correlation with clinicopathologic factors in invasive luminal subtype breast cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits